FoRx Therapeutics AG appoints Ulrich Lücking as
Head of Chemistry

Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking as Head of Chemistry.

Ulrich Lücking, PhD, is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his career Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.
Prior to joining industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr, and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.

About FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners). For more information, visit www.forxtherapeutics.com